BR112017002356A2 - composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos - Google Patents

composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos

Info

Publication number
BR112017002356A2
BR112017002356A2 BR112017002356A BR112017002356A BR112017002356A2 BR 112017002356 A2 BR112017002356 A2 BR 112017002356A2 BR 112017002356 A BR112017002356 A BR 112017002356A BR 112017002356 A BR112017002356 A BR 112017002356A BR 112017002356 A2 BR112017002356 A2 BR 112017002356A2
Authority
BR
Brazil
Prior art keywords
liquid formulation
preparing
methods
drug delivery
delivery devices
Prior art date
Application number
BR112017002356A
Other languages
English (en)
Inventor
Gerry Ferguson James
Yu Li
Original Assignee
Shanghai Hightide Biopharmaceutical Ltd
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410390825.9A external-priority patent/CN105435227A/zh
Priority claimed from CN201410391083.1A external-priority patent/CN105362220A/zh
Priority claimed from CN201410391082.7A external-priority patent/CN105434346A/zh
Priority claimed from CN201410391084.6A external-priority patent/CN105435232A/zh
Application filed by Shanghai Hightide Biopharmaceutical Ltd, Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shanghai Hightide Biopharmaceutical Ltd
Publication of BR112017002356A2 publication Critical patent/BR112017002356A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0612—Eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0662—Ears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0662—Ears
    • A61M2210/0668—Middle ear

Abstract

trata-se de composições de formulação líquida e dispositivos de entrega de medicamento e métodos para preparar e usar os mesmos. por exemplo, a composição de formulação líquida compreende um solvente e partículas líquidas que incluem tensoativos e são dispersas no solvente. o tamanho médio volumétrico de partícula das partículas líquidas é menor do que cerca de 100 µm; a tensão de superfície da composição de formulação líquida é menor do que cerca de 60 mn/m; e o valor absoluto do potencial zeta é maior do que cerca de 15 mv. o vaso de contenção pode ser um aspersor ou um dispositivo de gotejamento.
BR112017002356A 2014-08-08 2014-09-30 composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos BR112017002356A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410390825.9A CN105435227A (zh) 2014-08-08 2014-08-08 一种液体制剂组合物及其制备方法、用途和固体制剂
CN201410391083.1A CN105362220A (zh) 2014-08-08 2014-08-08 一种制剂及其制备方法、用途
CN201410391082.7A CN105434346A (zh) 2014-08-08 2014-08-08 一种制剂组合物及其制备方法、用途
CN201410391084.6A CN105435232A (zh) 2014-08-08 2014-08-08 一种液体制剂组合物及其制备方法、用途和制剂
PCT/CN2014/088010 WO2016019627A1 (en) 2014-08-08 2014-09-30 Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
BR112017002356A2 true BR112017002356A2 (pt) 2017-11-28

Family

ID=55263070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002356A BR112017002356A2 (pt) 2014-08-08 2014-09-30 composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos

Country Status (13)

Country Link
US (4) US20170182063A1 (pt)
EP (1) EP3177271A4 (pt)
JP (2) JP2017529313A (pt)
KR (1) KR20230019268A (pt)
AU (1) AU2014403039B2 (pt)
BR (1) BR112017002356A2 (pt)
CA (1) CA2945604C (pt)
IL (1) IL250510B (pt)
MX (1) MX2017001812A (pt)
NZ (1) NZ728487A (pt)
SG (1) SG11201700484SA (pt)
WO (1) WO2016019627A1 (pt)
ZA (1) ZA201700697B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120928A1 (en) * 2014-11-03 2016-05-05 Zent, Inc. Nasal spray
US10308897B2 (en) 2017-04-24 2019-06-04 Gpcp Ip Holdings Llc Alkaline sanitizing soap preparations containing quaternary ammonium chloride agents
CN107970230B (zh) * 2017-11-10 2020-04-28 华南理工大学 一种能瓦解和抑制细菌生物被膜的生成的皮克林乳液及其制备和应用
EP3720533B1 (en) * 2017-12-05 2023-08-23 Maquet Critical Care AB Piercing assembly and breathing conduit kit
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
WO2021250635A1 (en) * 2020-06-11 2021-12-16 Vyome Therapeutics Inc. Acid salts of fluoroquinolone carboxylic acid based compositions and methods of making and using the same
CN111603485A (zh) * 2020-07-09 2020-09-01 长沙善福喜科技有限公司 一种治疗鼻炎的药物组方和制备方法
WO2023122003A1 (en) * 2021-12-21 2023-06-29 Isp Investments Llc An antimicrobial liquid composition, process for preparing the same and method of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0053754B1 (de) * 1980-12-06 1986-04-23 Reichert, Dietrich, Dr. med. Mittel zur Bekämpfung des Schnarchens und Verfahren zu dessen Anwendung
US4863725A (en) * 1982-10-27 1989-09-05 Deckner George E Novel clear oil-free moisturizer composition
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
JPH10348A (ja) * 1996-06-13 1998-01-06 Mikimoto Pharmaceut Co Ltd エマルジョン
JP2002543165A (ja) * 1999-05-03 2002-12-17 バテル・メモリアル・インスティテュート エーロゾル化および吸入のための組成物
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
AR034200A1 (es) * 2001-01-12 2004-02-04 Novartis Ag Agente para el cuidado de lentes de contacto, su uso, y procedimiento de limpieza
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
DE10323178A1 (de) * 2003-05-22 2004-12-09 Basf Ag Mischung, umfassend ein Tensid und ein Cotensid
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425795D0 (en) * 2004-11-24 2004-12-22 Givaudan Sa Composition
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
CN100500773C (zh) * 2005-05-18 2009-06-17 江南大学 一种数字喷墨印花墨水及其制备方法
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
JP5351376B2 (ja) * 2006-05-24 2013-11-27 株式会社 資生堂 水中油型乳化化粧料
DE102006027138A1 (de) * 2006-06-08 2007-12-13 Beiersdorf Ag O/W Emulsion zur Pflege der Hand
AU2007297691B2 (en) * 2006-09-19 2013-12-19 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
WO2008148573A2 (de) * 2007-06-08 2008-12-11 Bayer Consumer Care Ag Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen
NL2002214C2 (en) * 2008-11-17 2010-05-18 Louis Johan Wagenaar Contact lens care solution.
TW201206418A (en) * 2010-07-02 2012-02-16 Holden Brien Vision Inst Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
DE202010012255U1 (de) * 2010-09-07 2010-11-18 Krewel Meuselbach Gmbh Nasenspray
SG10201605008TA (en) * 2011-06-17 2016-07-28 Berg Llc Inhalable pharmaceutical compositions
CN103505419B (zh) * 2013-09-24 2016-01-13 上海纳米技术及应用国家工程研究中心有限公司 一种低表面张力的载氧脂质体及其制备方法

Also Published As

Publication number Publication date
CA2945604A1 (en) 2016-02-11
US20220040203A1 (en) 2022-02-10
US20230147517A1 (en) 2023-05-11
JP6876100B2 (ja) 2021-05-26
AU2014403039A1 (en) 2016-11-03
CA2945604C (en) 2022-08-23
US20170182063A1 (en) 2017-06-29
ZA201700697B (en) 2018-12-19
JP2019203001A (ja) 2019-11-28
WO2016019627A1 (en) 2016-02-11
JP2017529313A (ja) 2017-10-05
US20200261472A1 (en) 2020-08-20
EP3177271A4 (en) 2018-02-28
SG11201700484SA (en) 2017-02-27
NZ728487A (en) 2021-07-30
IL250510A0 (en) 2017-03-30
US11559531B2 (en) 2023-01-24
IL250510B (en) 2022-01-01
MX2017001812A (es) 2017-07-17
KR20230019268A (ko) 2023-02-08
EP3177271A1 (en) 2017-06-14
AU2014403039B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
BR112017002356A2 (pt) composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
PH12016502205A1 (en) Biphasic cosmetic
BR112017007141A2 (pt) composição adesiva permutável, método para fixar uma composição adesiva permutável, e, uso de uma composição.
GB201704205D0 (en) Opthalmic delivery device and opthalmic active agent containing compositions
MX2017006148A (es) Composiciones para el cuidado personal con dos fases beneficas.
PH12018502615A1 (en) Depot formulations
UY36248A (es) ?una dispersión a base de agua o aceite, formulaciones y método para prepararlas, y uso de las dispersiones o formulaciones?.
MX2019008845A (es) Metodos y sistemas para mejorar la estabilidad de la formulacion prevapor de un dispositivo de vapeo electronico.
CL2016001104A1 (es) Preparación farmacéutica y método de su producción y uso.
AR086350A1 (es) Composiciones para el tratamiento del cabello, uso, metodo, procedimiento
BR112017000614A2 (pt) composição de liberação controlada, método para quebra de um fluido líquido de fraturamento, formulação de revestimento pulverizável, e método de revestimento de um material solúvel em água na forma de grânulos com uma formulação pulverizável
MX2019002921A (es) Composiciones para el cuidado bucal y sistema para dispensar las mismas.
MY184693A (en) Bilayer hydrocolloid films containing therapeutic agents
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
FR3021530B1 (fr) Composition de protection solaire sous forme d'emulsion huile-dans-eau comprenant au moins un melange de tensioactifs
MX2018006775A (es) Metodos y composiciones para tratar una corriente que comprende petroleo crudo y agua.
PH12017501563A1 (en) Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems
EP3210614A4 (en) Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
WO2015199966A3 (en) Skin treatment composition
EA201991594A1 (ru) Депо-препарат
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
EP3603400A4 (en) LIQUID COPPER BASED FORMULATION FOR IMPROVING SELF-DEFENSE IN PLANTS AND USING THEM
MX2017011717A (es) Composiciones liquidas concentradas emulsionables y procedimientos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09R Decision of refusal: republication [chapter 9.2.3 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE INDEFERIMENTO NOTIFICADO NA RPI NO 2719 DE 14/02/2023, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES (INCONSISTENCIAS ENTRE OS QUADROS 3 E 5 E O CONTEUDO DO PARECER TECNICO), ASSIM REPUBLICO A REFERIDA PUBLICACAO.

B12B Appeal against refusal [chapter 12.2 patent gazette]